Assisted Reproduction
SJ02
Follicle-stimulating hormone (FSH) is a glycoprotein hormone produced and secreted by the basophilic cells of the anterior pituitary gland. In males, it promotes the development of spermatogenic epithelium, the initiation of sperm production, and sperm maturation. In females, it stimulates follicular development and maturation, works together with luteinizing hormone to prompt mature follicles to secrete estrogen and ovulate, and is involved in the formation of normal menstrual cycles. For patients undergoing superovulation or assisted reproductive technologies, FSH can stimulate the development of multiple follicles.
SJ02 (FSH-CTP) is a long-acting form of FSH with modified glycosylation sites. It does not alter its biological activity but has a prolonged half-life, 2-3 times longer than that of FSH. Unlike conventional short-acting FSH, which requires daily injections for 10-14 days, SJ02 can replace a week's worth of these injections with just a single dose. This not only ensures the effectiveness and safety of treatment but also improves the patient experience, reduces the workload on medical institutions, and lowers healthcare costs.
The production process of SJ02 is complex, with significant technical barriers in expression and purification, and there was a technological gap in this field in China. Bao Pharma's independently developed SJ02, the first domestic recombinant FSH-CTP product, has successfully broken the monopoly of foreign products, enhancing China's international competitiveness in biopharmaceutical technology. It also reduces the medication costs and alleviates patients’ physical and psychological distress.